Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.003 per share
-
Shares outstanding
-
792,553,191
-
Total 13F shares
-
7,275,071
-
Share change
-
+3,993,008
-
Total reported value
-
$22,263,000
-
Price per share
-
$3.06
-
Number of holders
-
20
-
Value change
-
+$12,610,604
-
Number of buys
-
14
-
Number of sells
-
5
Institutional Holders of Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) as of Q2 2020
As of 30 Jun 2020,
Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,275,071 shares.
The largest 10 holders included
BOXER CAPITAL, LLC, Vivo Capital, LLC, PRIMECAP MANAGEMENT CO/CA/, Verition Fund Management LLC, Point72 Asset Management, L.P., Marshall Wace North America L.P., DRIEHAUS CAPITAL MANAGEMENT LLC, Logos Global Management LP, HILLHOUSE CAPITAL ADVISORS, LTD., and Jefferies Group LLC.
This page lists
20
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.